Business
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment
The new data was presented at the SITC 2020 Virtual Scientific Program MARLBOROUGH, Mass., Nov. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq:
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"The new data was presented at the SITC 2020 Virtual Scientific Program\n\n\nMARLBOROUGH, Mass., Nov. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive data from an in vivo study that shows the strong antitumoral efficacy of individual INTASYL pipeline products, including PH-762, PH-790 and PH-804, can be further improved by combining them in a single therapeutic. These data were presented during The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting - Abstract 198: \"Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer \".\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg \nThese results build on previously published data showing that intratumoral delivery of individual INTASYL compounds inhibited tumor growth. The data presented at SITC 2020 demonstrated that such antitumoral effect can be significantly improved by combining different INTASYL compounds. Therefore, the Company believes the use of our pipeline products in combination show great promise in the treatment of solid tumors. \nThe Company's pipeline programs PH-762, PH-790 and PH-804 are INTASYL compounds designed to silence the expression of PD-1, PD-L1 and TIGIT, respectively, which are proteins linked to reduced immune cell function in cancer patients. Previously, a series of preclinical in vivo studies in tumor models were conducted and the resulting data showed dose-dependent attenuated tumor growth for the INTASYL compounds compared to control groups. The new data shows that whereas in vivo efficacy of INTASYL monotherapy was analogous to that of systemically delivered antibody therapy for each target, combining INTASYL targeting TIGIT + PD-1 or TIGIT + PD-L1 inhibited tumor growth even further, without having a negative impact on the tolerability of the treatment.\n\"Recent study results with systemic immune checkpoint blockade antibody therapies shows promise of combination therapy, but the serious immune-related adverse events seen with such antibody therapy results in...